<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427464</url>
  </required_header>
  <id_info>
    <org_study_id>VMDN-003</org_study_id>
    <nct_id>NCT02427464</nct_id>
  </id_info>
  <brief_title>Phase 3 Gene Therapy for Painful Diabetic Neuropathy</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helixmith Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helixmith Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of bilateral intramuscular&#xD;
      injections of VM202 versus placebo in the treatment of painful diabetic neuropathy.&#xD;
&#xD;
      A total of 477 subjects will be randomized in a 2:1 ratio to one of two treatment groups:&#xD;
&#xD;
      Treatment - VM202 - 318 subjects Control - Placebo (VM202 vehicle) - 159 subjects&#xD;
&#xD;
      Randomization will be stratified by current use of gabapentin and/or pregabalin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral neuropathy is a serious complication of diabetes. This form of neuropathy carries&#xD;
      a high risk of pain, trophic changes and autonomic dysfunction. Treatment of diabetic&#xD;
      peripheral neuropathy (DPN) is based on either pathogenetic mechanisms or symptomatic relief.&#xD;
      A number of clinical trials have established symptomatic treatment but for pathogenetic&#xD;
      mechanisms, the only proven treatment strategy is strict glycemic control. Clearly, it would&#xD;
      be desirable to prevent, impede, or reverse the disrupting and often life-threatening&#xD;
      manifestations of peripheral neuropathy by stimulating growth or regeneration of peripheral&#xD;
      nerve axons. The results from previous studies suggest that VM202 provides the same magnitude&#xD;
      of pain relief as reported with pregabalin or gabapentin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the average pain score</measure>
    <time_frame>Baseline to three month follow up</time_frame>
    <description>Subjects complete a Daily Pain and Sleep Interference diary at Screening (following wash-out of prohibited medications), and Day 90</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome of at least 50% reduction in average pain score</measure>
    <time_frame>Baseline to three month follow up</time_frame>
    <description>Subjects complete a Daily Pain and Sleep Interference diary at Screening (following wash-out of prohibited medications), and Day 90</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the average pain score</measure>
    <time_frame>Baseline to Six month follow up</time_frame>
    <description>Subjects complete a Daily Pain and Sleep Interference diary at Screening (following wash-out of prohibited medications), Day 90, Day 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of at least 50% reduction in average pain score</measure>
    <time_frame>Baseline to Six month follow up</time_frame>
    <description>Subjects complete a Daily Pain and Sleep Interference diary at Screening (following wash-out of prohibited medications), Day 90, and Day 180</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">507</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <condition>Diabetic Neuropathy, Painful</condition>
  <arm_group>
    <arm_group_label>VM202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the VM202 treatment arm will receive the following intramuscular injections in each calf:&#xD;
Day 0 - 16 injections of 0.5mL of VM202 / calf&#xD;
Day 14 - 16 injections of 0.5mL of VM202 / calf&#xD;
Day 90 - 16 injections of 0.5mL of VM202 / calf&#xD;
Day 104 - 16 injections of 0.5mL of VM202 / calf</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the placebo control group will receive the following intramuscular injections in each calf:&#xD;
Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf&#xD;
Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf&#xD;
Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf&#xD;
Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM202</intervention_name>
    <description>gene therapy</description>
    <arm_group_label>VM202</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years to 75 years;&#xD;
&#xD;
          2. Documented history of Type I or II diabetes with current treatment control&#xD;
             (glycosylated hemoglobin A1c of ≤ 10.0% at Screening) and currently on oral medication&#xD;
             and / or insulin;&#xD;
&#xD;
          3. No significant changes anticipated in diabetes medication regimen;&#xD;
&#xD;
          4. No new symptoms associated with diabetes within the last 3 months prior to study&#xD;
             entry;&#xD;
&#xD;
          5. Diagnosis of painful diabetic peripheral neuropathy in both lower extremities;&#xD;
&#xD;
          6. Lower extremity pain for at least 6 months;&#xD;
&#xD;
          7. Visual analog scale (VAS) score of ≥ 40 mm at Initial Screening (0 mm = no pain - 100&#xD;
             mm very severe pain);&#xD;
&#xD;
          8. Symptoms from the Brief Pain Neuropathy Screening (BPNS) is ≤ 5 point difference&#xD;
             between legs at Initial Screening;&#xD;
&#xD;
          9. The average daily pain intensity score of the Daily Pain and Sleep Interference Diary&#xD;
             completed after medication wash-out is ≥ 4 with a standard deviation ≤ 2;&#xD;
&#xD;
         10. The physical examination component of the Michigan Neuropathy Screening Instrument&#xD;
             Score (MNSI) is ≥ 3 at Initial Screening;&#xD;
&#xD;
         11. Subjects on gabapentin (Neurontin), pregabalin (Lyrica), duloxetine (Cymbalta) for&#xD;
             painful DPN at study entry must be on stable regimen of these treatments for at least&#xD;
             3 months prior to study entry; and&#xD;
&#xD;
         12. If female of childbearing potential, negative urine pregnancy test at screening and&#xD;
             using acceptable method of birth control during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Peripheral neuropathy caused by condition other than diabetes;&#xD;
&#xD;
          2. Other pain more severe than neuropathic pain that would prevent assessment of DPN;&#xD;
&#xD;
          3. Progressive or degenerative neurological disorder;&#xD;
&#xD;
          4. Myopathy;&#xD;
&#xD;
          5. Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's&#xD;
             disease);&#xD;
&#xD;
          6. Active infection;&#xD;
&#xD;
          7. Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis);&#xD;
&#xD;
          8. Positive HIV or HTLV at Screening;&#xD;
&#xD;
          9. Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb), antibody&#xD;
             to Hepatitis B surface antigen (IgG and IgM; HBsAb), Hepatitis B surface antigen&#xD;
             (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening;&#xD;
&#xD;
         10. Subjects with known immunosuppression or currently receiving immunosuppressive drugs,&#xD;
             chemotherapy or radiation therapy;&#xD;
&#xD;
         11. Stroke or myocardial infarction within last 3 months;&#xD;
&#xD;
         12. Specific laboratory values at Screening including: Hemoglobin &lt; 8.0 g/dL, WBC &lt; 3,000&#xD;
             cells per microliter, platelet count &lt;75,000/mm3, Creatinine &gt; 2.0 mg/dL; AST and/or&#xD;
             ALT &gt; 3 times the upper limit of normal or any other clinically significant lab&#xD;
             abnormality which in the opinion of the investigator should be exclusionary;&#xD;
&#xD;
         13. Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that&#xD;
             preclude standard ophthalmologic examination;&#xD;
&#xD;
         14. Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) &gt; 200&#xD;
             mmHg or diastolic BP (DBP) &gt; 110 mmHg at Screening;&#xD;
&#xD;
         15. Subjects with a recent history (&lt; 5 years) of or new screening finding of malignant&#xD;
             neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if&#xD;
             excised and no evidence of recurrence for one year); subjects with family history of&#xD;
             colon cancer in any first degree relative are excluded unless they have undergone a&#xD;
             colonoscopy in the last 12 months with negative findings;&#xD;
&#xD;
         16. Use of the following drugs / therapeutics is PROHIBITED. Subjects may participate in&#xD;
             the study if they are willing to discontinue use of these drugs / therapeutics 7 days&#xD;
             prior to starting the 7 Day Daily Pain and Sleep Interference Diary. Subjects must&#xD;
             refrain from taking these drugs or undergoing these therapies for the duration of the&#xD;
             study:&#xD;
&#xD;
               -  skeletal muscle relaxants, opioids, benzodiazepines (except for stable bedtime&#xD;
                  dose),&#xD;
&#xD;
               -  capsaicin, local anesthetic creams and patches, isosorbide dinitrate (ISDN)&#xD;
                  spray,&#xD;
&#xD;
               -  transcutaneous electrical nerve stimulation (TENS), acupuncture&#xD;
&#xD;
         17. If not using gabapentin (Neurontin) or pregabalin (Lyrica), subjects must agree not to&#xD;
             start these drugs for the first 6 months of the study. Subjects on these medications&#xD;
             at study entry must maintain a stable dose for the first 6 months of the study;&#xD;
&#xD;
         18. If not using duloxetine (Cymbalta), any antidepressants (e.g. amitriptyline and&#xD;
             venlafaxine), any other antiepileptics (e.g., valproic acid, carbamazepine,&#xD;
             vigabatrin), subjects must agree not to start these drugs for the first 6 months of&#xD;
             the study.&#xD;
&#xD;
             Subjects on these medications at study entry must maintain a stable dose for the first&#xD;
             6 months of the study;&#xD;
&#xD;
         19. Subjects requiring &gt; 81 mg daily of acetylsalicylic acid; subjects may be enrolled if&#xD;
             willing/able to switch to ≤ 81 mg daily of acetylsalicylic acid or to another&#xD;
             medication;&#xD;
&#xD;
         20. Subjects requiring regular COX-2 inhibitor drug(s) or non-specific COX-1/COX-2&#xD;
             inhibiting drugs, or high dose steroids (except inhaled steroids or ocular steroids);&#xD;
             subjects may be enrolled if willing/able to undergo medication wash-out prior to the&#xD;
             first dosing and to refrain from taking these drugs for the first 6 months of the&#xD;
             study;&#xD;
&#xD;
         21. Major psychiatric disorder within last 6 months that would interfere with study&#xD;
             participation;&#xD;
&#xD;
         22. Body mass index (BMI) &gt; 45 kg/m2 at Screening;&#xD;
&#xD;
         23. Any lower extremity amputation due to diabetic complications;&#xD;
&#xD;
         24. Use of an investigational drug or treatment in past 6 months, or prior participation&#xD;
             in any study of VM202; and&#xD;
&#xD;
         25. Unable or unwilling to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Kessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard S. Cherlin, MD</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern Connecticut, PC</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida McKnight Brain Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health College of Med, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>56001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center Department of Neurology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates, P.A.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Foot and Ankle</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nerve and Muscle Center of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>56001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah -Neurology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EVMS (Eastern Virginia Medical School)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Washington Medical Group</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 22, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic</keyword>
  <keyword>neuropathy</keyword>
  <keyword>shooting pain</keyword>
  <keyword>burning pain</keyword>
  <keyword>pins and needles pain</keyword>
  <keyword>foot pain</keyword>
  <keyword>ViroMed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

